Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a…